BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 29846847)

  • 1. Long-term breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes.
    Andersson Y; Bergkvist L; Frisell J; de Boniface J
    Breast Cancer Res Treat; 2018 Sep; 171(2):359-369. PubMed ID: 29846847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of axillary dissection in breast cancer patients with micrometastases or isolated tumor cells in sentinel nodes: a nationwide study.
    Tvedskov TF; Jensen MB; Ejlertsen B; Christiansen P; Balslev E; Kroman N
    Breast Cancer Res Treat; 2015 Oct; 153(3):599-606. PubMed ID: 26341752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evolution of the sentinel node procedure in the treatment of breast cancer.
    Tvedskov TF
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes.
    Andersson Y; Frisell J; Sylvan M; de Boniface J; Bergkvist L
    J Clin Oncol; 2010 Jun; 28(17):2868-73. PubMed ID: 20458033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of sentinel lymph node biopsy prior to axillary lymph node dissection: the role of isolated tumor cells/micrometastases and multifocality/multicentricity-a retrospective study of 1214 breast cancer patients.
    Schröder L; Fricker R; Stein RG; Rink T; Fitz H; Blasius S; Wöckel A; Müller T
    Arch Gynecol Obstet; 2018 Jun; 297(6):1509-1515. PubMed ID: 29594495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Staging of women with breast cancer after introduction of sentinel node guided axillary dissection.
    Tvedskov TF
    Dan Med J; 2012 Jul; 59(7):B4475. PubMed ID: 22759850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sentinel lymph nodes with isolated tumour cells and micrometastases in breast cancer: clinical relevance and prognostic significance.
    Ahmed SS; Thike AA; Iqbal J; Yong WS; Tan B; Madhukumar P; Ong KW; Ho GH; Wong CY; Tan PH
    J Clin Pathol; 2014 Mar; 67(3):243-50. PubMed ID: 24218025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic value of sentinel lymph node micrometastases in patients with invasive breast carcinoma.
    Cipolla C; Graceffa G; La Mendola R; Fricano S; Fricano M; Vieni S
    Ann Ital Chir; 2015; 86():497-502. PubMed ID: 26898168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of isolated tumor cells and micrometastases of lymph nodes in early-stage breast cancer: a French sentinel node multicenter cohort study.
    Houvenaeghel G; Classe JM; Garbay JR; Giard S; Cohen M; Faure C; Hélène C; Belichard C; Uzan S; Hudry D; Azuar P; Villet R; Penault Llorca F; Tunon de Lara C; Goncalves A; Esterni B;
    Breast; 2014 Oct; 23(5):561-6. PubMed ID: 24874284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Sentinel Node with Isolated Breast Tumor Cells or Micrometastases. Benefits and Risks of Axillary Dissection.
    Madekivi V; Boström P; Aaltonen R; Vahlberg T; Salminen E
    Anticancer Res; 2017 Jul; 37(7):3757-3762. PubMed ID: 28668871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Observational study of axilla treatment for breast cancer patients with 1-3 positive micrometastases or macrometastases in sentinel lymph nodes.
    Oba MS; Imoto S; Toh U; Wada N; Kawada M; Kitada M; Masuda N; Taguchi T; Minami S; Jinno H; Sakamoto J; Morita S;
    Jpn J Clin Oncol; 2014 Sep; 44(9):876-9. PubMed ID: 25030214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological significance of occult micrometastases in histologically negative axillary lymph nodes in breast cancer patients using the recent American Joint Committee on Cancer breast cancer staging system.
    Kahn HJ; Hanna WM; Chapman JA; Trudeau ME; Lickley HL; Mobbs BG; Murray D; Pritchard KI; Sawka CA; McCready DR; Marks A
    Breast J; 2006; 12(4):294-301. PubMed ID: 16848838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical effect of the pathological axillary assessment method in breast cancer without clinical nodal metastasis.
    Sasada S; Masumoto N; Emi A; Kadoya T; Arihiro K; Okada M
    Breast Cancer; 2021 Sep; 28(5):1016-1022. PubMed ID: 33740208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Completion axillary lymph node dissection not required for regional control in patients with breast cancer who have micrometastases in a sentinel node.
    Yegiyants S; Romero LM; Haigh PI; DiFronzo LA
    Arch Surg; 2010 Jun; 145(6):564-9. PubMed ID: 20566977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omitting completion axillary lymph node dissection after detection of sentinel node micrometastases in breast cancer: first results from the prospective SENOMIC trial.
    Andersson Y; Bergkvist L; Frisell J; de Boniface J
    Br J Surg; 2021 Sep; 108(9):1105-1111. PubMed ID: 34010418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival impact and predictive factors of axillary recurrence after sentinel biopsy.
    Houvenaeghel G; Classe JM; Garbay JR; Giard S; Cohen M; Faure C; Charytansky H; Rouzier R; Daraï E; Hudry D; Azuar P; Villet R; Gimbergues P; Tunon de Lara C; Martino M; Fraisse J; Dravet F; Chauvet MP; Goncalves A; Lambaudie E
    Eur J Cancer; 2016 May; 58():73-82. PubMed ID: 26971077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sentinel lymph node biopsy in microinvasive ductal carcinoma in situ.
    Magnoni F; Massari G; Santomauro G; Bagnardi V; Pagan E; Peruzzotti G; Galimberti V; Veronesi P; Sacchini VS
    Br J Surg; 2019 Mar; 106(4):375-383. PubMed ID: 30791092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One Step Nucleic Acid Amplification (OSNA) positive micrometastases and additional histopathological NSLN metastases: Results from a single institution over 53 months.
    Babar M; Madani R; Jackson P; Layer GT; Kissin MW; Irvine TE
    Surgeon; 2016 Apr; 14(2):76-81. PubMed ID: 25444440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Micrometastases or isolated tumor cells and the outcome of breast cancer.
    de Boer M; van Deurzen CH; van Dijck JA; Borm GF; van Diest PJ; Adang EM; Nortier JW; Rutgers EJ; Seynaeve C; Menke-Pluymers MB; Bult P; Tjan-Heijnen VC
    N Engl J Med; 2009 Aug; 361(7):653-63. PubMed ID: 19675329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regional recurrence in breast cancer patients with sentinel node micrometastases and isolated tumor cells.
    Pepels MJ; de Boer M; Bult P; van Dijck JA; van Deurzen CH; Menke-Pluymers MB; van Diest PJ; Borm GF; Tjan-Heijnen VC
    Ann Surg; 2012 Jan; 255(1):116-21. PubMed ID: 22183034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.